Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

The HER2-specific tyrosine kinase inhibitor tucatinib, combined with trastuzumab and capecitabine, showed improved survival as compared with trastuzumab and capecitabine in patients with heavily ...

The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most ...

Trastuzumab deruxtecan (Enhertu; AstraZeneca/Daiichi Sankyo) in combination with pertuzumab (Perjeta; Genentech) demonstrated significantly longer progression-free survival (PFS) compared with the ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with ado-trastuzumab emtansine among previously treated patients with HER2-positive unresectable or metastatic ...

Trastuzumab deruxtecan (6.4 mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ ...

The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed despite earlier trastuzumab-based therapy.

Clinical response to trastuzumab was assessed by tumor measurements on day 22 before chemotherapy. Core biopsies were assessed by immunohistochemistry for cell cycle and proliferation (Ki67, p27, ...